SPRC Stock Catalyst: SciSparc Ltd. Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

Oct 23, 2026 · 5:43am ET

NeuroThera Labs, a subsidiary of SciSparc, announced the progress.

Max move

+45.1%

High of day $1.91

Sparker timei

5:43am ET

SPRC · Oct 23, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

SciSparc Ltd. (Nasdaq: SPRC) announced that its subsidiary, NeuroThera Labs, has reported positive progress in the FDA-approved Phase IIb clinical trial for Tourette syndrome. The announcement was made via a 6-K filing on October 23, 2026.

The filing did not provide specific data or outcomes from the trial but indicated that the progress was positive. The trial is ongoing, and further details are expected in future filings.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time SPRC sparks.

Download Sniper App →

Catch the next SPRC-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

SPRC Stock Catalyst: SciSparc Ltd. Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome

SPRC · Oct 23, 2026

SPRC · Oct 23, 2026

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.